RVMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Revolution Medicines Inc (RVMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including significant analyst optimism, upcoming catalysts in 2026, and M&A speculation. While technical indicators are neutral, the SwingMax signal and analyst confidence suggest a favorable entry point.
The MACD histogram is -0.296, below 0, and negatively contracting, indicating a neutral to slightly bearish momentum. RSI is at 67.828, in the neutral zone, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend. Key resistance levels are at 102.313 and 104.649, with support at 94.749 and 92.413. Current pre-market price is 102.8, near resistance levels.
Analysts maintain high confidence in RVMD, with multiple price target increases (e.g., JPMorgan to $122, Oppenheimer to $150, Stifel to $170).
M&A speculation remains strong, with RVMD seen as a potential acquisition target.
Upcoming catalysts in 2026, including the RASolute 302 readout, are expected to drive investor interest.
SwingMax signal indicates a buy opportunity.
Recent news of Merck no longer pursuing acquisition talks caused a temporary drop in share price.
Financial performance shows negative net income and EPS, though improving YoY.
Options data shows a balanced sentiment with a Put-Call Ratio close to 1, indicating no overwhelming bullish sentiment.
In Q3 2025, revenue remained at 0 with no YoY growth. Net income improved significantly YoY by 95.28% to -$305.2M, while EPS improved by 71.28% to -1.61. Gross margin remained at 0. The company is not yet profitable but shows improving trends in reducing losses.
Analysts are overwhelmingly positive on RVMD, with multiple firms raising price targets significantly (e.g., JPMorgan to $122, Oppenheimer to $150, Stifel to $170). The stock is seen as a top pick for 2026 due to its potential in oncology and M&A speculation. Analysts also highlight the scarcity value of its pan-RAS inhibitors and upcoming catalysts.
